Primary prevention implantable cardioverter-defibrillator (ICD) therapy maintained a survival advantage for recipients in the extended term, although not constant for all sorts of heart failure (HF), researchers located.
In an extended adhere to-up of the 1,855 sufferers alive at the finish of the SCD-HeFT trial, mortality at 10 years was 52.five% in these randomized to an ICD, 52.7% in these randomized to amiodarone, and 57.two% amongst controls assigned to placebo medication.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.